Patients who received higher doses of tisagenlecleucel had improved overall survival, event-free survival, and relapse-free survival, with no increased toxicity.
Childhood cancer survivors have an increased risk of inpatient infections 5 years or more after their cancer diagnosis.
Researchers found clinically significant genetic variations in 86% of pediatric patients with extracranial solid tumors.
Researchers are conducting a phase 1/2 trial to evaluate durvalumab plus tremelimumab in pediatric patients with advanced cancers.
Researchers are conducting a phase 1/2 trial of avapritinib in pediatric patients who have relapsed or refractory solid tumors with mutations in KIT or PDGFRA or who have H3K27M-mutant glioma.
Researchers are conducting a phase 1/2 trial to test alectinib in pediatric patients with ALK fusion-positive solid tumors or CNS tumors.
Researchers aim to determine if memantine can protect neurocognitive function in pediatric patients undergoing cranial radiotherapy to treat CNS tumors.
Race and ethnicity were reported in less than 25% of the trials studied.
Disparities in cancer diagnoses among pediatric patients are partly a result of disparities in health insurance coverage, a study suggests.
Dinutuximab plus GM-CSF produced a low disease control rate that did not meet a historical benchmark.
BMP4 could be a therapeutic target in B-cell precursor acute lymphoblastic leukemia.
There was no significant difference in overall survival between patients who received actinomycin-D and those who received carboplatin.
The global burden of childhood cancer decreased from 1990 to 2019, and the greatest decrease was seen for leukemia.
Tisagenlecleucel can produce responses in children and young adults with relapsed/refractory B-cell non-Hodgkin lymphoma, a phase 2 study suggests.
The accelerated approval was based on data from two phase 2 trials: the ROAR basket study and the NCI-MATCH Subprotocol H study.
Researchers are conducting a phase 1/2 trial to assess the safety and efficacy of combination repotrectinib, irinotecan, and temozolomide.
Researchers are conducting a phase 1 trial to assess the safety and efficacy of RRx-001 in combination with irinotecan and temozolomide.
Researchers are conducting a phase 1 trial of ibrutinib plus indoximod, cyclophosphamide, and etoposide in patients with brain cancers.
Researchers will assess toxicity and pharmacokinetics in phase 1 and the antitumor activity of nivatrotamab in phase 2.
Patients with sonic hedgehog medulloblastoma and Li-Fraumeni syndrome have a “dismal” prognosis, according to researchers.